Scutellarin Aglycone Crystal Forms for Oral Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Scutellarin aglycone has poor oral absorption and low oral availability due to its complex components and instability, making it challenging for effective drug development and industrial production.
Innovation Solution
Preparation of multiple stable crystal forms of scutellarin aglycone through methods like slow evaporation, crystallization, and ionic liquid-induced crystallization, which enhance its stability and purity, leading to improved oral absorption and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If scutellarin is used as a crude drug, then it has complex components, but it is difficult to control quality and has poor oral absorption
Solution Approach 1:
The patent extracts and isolates scutellarin aglycone from the complex crude drug mixture through purification processes. This removes the problematic complex components while retaining the active therapeutic principle, enabling quality control through a single well-defined compound rather than a mixture.
Solution Approach 2:
The patent changes the chemical structure parameter by converting scutellarin to its aglycone form (scutellarein). This structural modification fundamentally alters the compound's properties, including dramatically improving oral absorption from poor to excellent while maintaining therapeutic activity.
2Reliability
If scutellarin is purified to obtain scutellarin aglycone, then oral absorption improves, but stability and crystallization become challenges
Solution Approach 1:
The patent utilizes controlled phase transitions during crystallization to stabilize scutellarin aglycone. By carefully controlling solvent evaporation, temperature changes, and pH conditions, the unstable aglycone is transformed into stable crystalline forms that can be stored and handled reliably.
Solution Approach 2:
The patent employs various solvents and buffers as intermediaries during the crystallization process. These intermediary substances facilitate the formation of stable crystal structures by mediating the interaction between scutellarin aglycone molecules and the environment, protecting the compound from degradation.
3Reliability
If multiple crystal forms are prepared, then stability and purity improve, but the preparation process becomes complex
Solution Approach 1:
The patent segments the preparation process into distinct methods for obtaining different crystal forms (Forms I-VI), each with specific stability and purity characteristics. This segmentation allows selection of the most appropriate crystal form for specific applications, balancing stability requirements with process complexity.
Solution Approach 2:
The patent systematically varies preparation parameters (solvent type, temperature, pH, evaporation rate) to generate different crystal forms. By understanding how parameter changes affect crystal structure, the patent provides a rational framework for selecting preparation conditions that achieve desired stability and purity without unnecessary complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stable crystal forms of scutellarin aglycone exhibit enhanced oral absorption and bioavailability, facilitating its conversion to scutellarin in vivo and improving its pharmacological activity, making it suitable for drug development and industrial production.
Implementation Method 1
Scutellarin aglycone is the hydrolysis product of scutellarin
Implementation Method 2
Preparation of multiple stable crystal forms of scutellarin aglycone through methods like slow evaporation, crystallization
Implementation Method 3
Preparation of multiple stable crystal forms of scutellarin aglycone through methods like slow evaporation, crystallization, and ionic liquid-induced crystallization
Data Source
AI summary
The invention belongs to the field of medicine and chemical industry, and particularly relates to multiple crystal forms of scutellarin aglycone and preparation thereof. The invention also relates to use of said crystal forms of scutellarin aglycone in the manufacture of a medicament for preventing and/or treating a cardiovascular or cerebrovascular disease, rheumatic arthritis or stroke sequelae, etc. The crystal forms of scutellarin aglycone according to the invention have good stability, and can solve the problems concerning poor oral absorption and low bioavailability of scutellarin.